GlassScriptPhysician profile
James C Kwiatkowski
NPI 1225607906
$2,271.96
in general payments reported to CMS, 2019-2025
20 companies · $897 in 2025
The $897 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $519 · 2024: $856 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.38 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $239.83 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $193.30 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $148.50 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $130.91 | 2023-2025 | Ingrezza |
| Corium, LLC | $128.51 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $108.50 | 2024 | Spravato |
| Neuronetics, INC. | $92.22 | 2024-2025 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $88.33 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.23 | 2025 | Caplyta |
| Lundbeck LLC | $74.51 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $73.47 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $71.39 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $69.96 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $57.72 | 2025 | Loreev Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $47.61 | 2025 | |
| Tms Neurohealth Centers INC. | $20.61 | 2025 | Tms Neurohealth Centers INC. |
| Neos Therapeutics, LP | $16.24 | 2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2024 | Trintellix |
| Noven Therapeutics, LLC | $15.19 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kwiatkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.